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SLEAbstract Aim of the work: To study the prevalence of thyroid dysfunction and anti-thyroid
antibodies (ATA) in Egyptian patients with systemic lupus erythematosus (SLE), and their associ-
ation with musculoskeletal manifestations of the disease.
Patients and methods: Cross sectional study included 100 SLE patients and 100 matched
controls. Clinical manifestations at any time during disease course were reported. Detailed muscu-
loskeletal examination was done using Ritchie articular index (RAI), 44-Swollen joint count and
ﬁbromyalgic tender points. Phalen’s test was used to diagnose carpal tunnel syndrome. Free-thyroid
hormones (FT3 and FT4), thyroid stimulating hormone (TSH), anti-thyroglobulin (anti-TG) and
anti-thyroid peroxidase (anti-TPO) antibodies were measured.
Results: The prevalence of thyroid dysfunction was signiﬁcantly higher in patients than controls
(18% vs. 4%, p= 0.003) and all were females. Prevalence of subclinical hypothyroidism (SCHT)
and clinical hypothyroidism (CHT) is 10% (p= 0.002) and 4% (p= 0.121) versus non among con-
trols while, that of subclinical hyperthyroidism (4%) was not signiﬁcantly different. Prevalence of
anti-TPO and anti-TG is higher in patients than controls (35% vs 11%, p< 0.001 and 22% vs. 6%,
p= 0.001). All patients with SCHT had anti-TPO and half of them had anti-TG while all patients
174 K.T. El-Hadidi et al.with CHT had both antibodies. Hypothyroidism was associated signiﬁcantly with aging (p= 0.01),
longer disease duration (p< 0.001), high BMI, high RAI scores, arthritis, positive Phalen’s test and
ﬁbromyalgia (p< 0.001 for all) in comparison to euthyroid patients.
Conclusion: Hypothyroidism was more prevalent in SLE patients and its detection is recom-
mended to reduce the risk of musculoskeletal related morbidity.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic, autoim-
mune, multifaceted inﬂammatory disease often associated with
other organ-speciﬁc autoimmune diseases [1]. Autoimmune
thyroiditis is an organ-speciﬁc disease and its association
with thyroid dysfunction and SLE was reported in several
studies and yielded conﬂicting conclusions. While some
studies reported higher prevalence of hypothyroidism in SLE
patients others reported higher prevalence of hyperthyroidism
[2–8]. The association between thyroid dysfunction and SLE
was ﬁrst reported by White et al. [9] and Hijmans et al. [10]
in 1961, who showed that the thyroid dysfunction appeared
more common in SLE than in general population. Thyroid
involvement being non-life-threatening than other organ
involvement in SLE, it is often underestimated and passes
undetected for long contributing to the morbidity of the illness.
So, it is important to diagnose the thyroid dysfunction in lupus
patients and to treat them accordingly [2]. The aim of this
study was to estimate the prevalence of thyroid dysfunction
and anti-thyroid antibodies in Egyptian SLE patients and their
association with the musculoskeletal manifestations of the
disease.2. Patients and methods
2.1. Patients
A cross sectional case–control study included 100 Egyptian
SLE patients who met the American College of Rheumatology
Classiﬁcation criteria of SLE [11,12] with age more than 18
and had at least 5-year disease duration and 100 age and sex
matched apparently healthy individuals served as control.
The patients were recruited from the Maadi Armed Force
Hospital during the period from October 2011 till October
2012. Demographic data and clinical manifestations at any
time during the disease course were reported for all patients.
Patients with thyroid disease, thyroid medications or thyroid-
ectomy were excluded from the study. All participants
provided written informed consent prior to their inclusion.
This study was approved by the local ethics committees and
in accordance with the ethical standards laid down in the
1964 declaration of Helsinki.
Full history taking and clinical examination were done tak-
ing into consideration the symptoms and signs of thyroid dys-
functions. Detailed musculoskeletal examination was done.
Assessment of joint tenderness was done using the Ritchie
articular index (RAI), 53 joints in 26 units, graded according
to tenderness on pressure (0 = no pain; 1 = patient complainsof pain; 2 = patient complains of pain and winces; 3 = patient
complains, winces, and withdraws; maximum score 78) [13].
Assessment of joint swelling was done using the 44-Swollen
joint count [14]. Fibromyalgic tender points were scored for
each patient [15]. Phalen’s test was used to diagnose clinically
the carpal tunnel syndrome. This test was considered positive if
there were paraesthetic symptoms along the cutaneous distri-
bution of median nerve after maintaining maximal wrist ﬂex-
ion for one minute [16].
2.2. Laboratory investigations
Routine laboratory investigations for patients with SLE were
done including complete blood count (CBC), erythrocyte sed-
imentation rate (ESR), serum alanine transaminase (ALT),
aspartate transaminase (AST), creatinine, complete urine
analysis, 24 h urinary proteins, C3 and C4, anti-nuclear
antibody (ANA), and anti-double stranded DNA (anti-ds-
DNA).2.2.1. Thyroid hormones and thyroid stimulating hormone
(TSH) measurements
The sera were examined for free triido thyronine (FT3), free
thyroxine (FT4) and TSH by micro-particle enzyme immuno-
assay. The normal reference range for FT3 is 1.8–4.6 pg/ml,
for FT4 is 1.0–1.8 ng/dl and for TSH is 0.3–4.2 lIU/ml accord-
ing to Bemben et al. [17] and Bell et al. [18]. Elevated TSH with
low thyroid hormones was categorized as clinical hypothyroid
(CHT), while those with high TSH with normal thyroid hor-
mones were considered as subclinical hypothyroid (SCHT).
Similarly, low TSH with raised thyroid hormones and normal
thyroid hormones was called clinical hyperthyroid and subclin-
ical hyperthyroid, respectively [2].
2.2.2. Anti-thyroid antibodies (ATA) measurements
Serum anti-thyroglobulin antibodies (anti-TG) and anti-thy-
roid peroxidase antibodies (anti-TPO) were measured by im-
mune-metric assays. Antibodies were considered positive if
levels were >1 IU/ml for anti-TG and >50 IU/ml for anti-
TPO.
Statistical analysis: Data entry, processing and statistical
analysis were carried out using Statistical Package for the So-
cial Sciences version 20 (SPSS Inc., USA). Data were reported
as mean ± standard deviation (SD). Tests of signiﬁcance (stu-
dent t-test, Chi-square test with Fisher’s exact test, and Yates
correction were used when appropriate) were used to compare
between different groups. p values <0.05 was considered to be
statistically signiﬁcant.
Table 1 Demographic, clinical manifestations and laboratory
tests of lupus patients.
Demographic, clinical manifestations
at any time of the disease course and laboratory tests
Number (%)
Demographic data
Mean age (years)±SD 38.5 ± 13.5
Female/male (ratio) 9:1
Disease duration (years)±SD 12 ± 6.3
Clinical manifestations
Malar rash 65 (65%)
Discoid rash 13 (13%)
Photosensitivity 72 (72%)
Oral ulcers 63 (63%)
Arthritis/arthralgia 92 (92%)
Serositis
Pleuritis 31 (31%)
Pericarditis 14 (14%)
Nephritis 28 (28%)
Neurologic
Seizures 2 (2%)
Headache 3 (3%)
Psychiatric (depression) 2 (2%)
Laboratory
Anemia 35 (35%)
Leukopenia 39 (39%)
Thrombocytopenia 14 (14%)
ANA 97 (97%)
Anti ds-DNA 94 (94%)
Anti-Sm antibodies 15 (15%)
ANA, antinuclear antibody.
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3.1. SLE manifestations
Demographic data, clinical manifestations and laboratory tests
of SLE patients were shown in Table 1. Arthritis/arthralgia,
photosensitivity, malar rash, oral ulcers, serositis and nephritis
were found to be the most frequent clinical manifestations
and the neuro-psychiatric manifestations were the least
frequent.
3.2. Mean serum level of free-thyroid hormones, TSH and ATA
among patients and controls
Although, the mean serum level of FT3, FT4 and TSH was
within normal range among patients, but they were statistically
elevated in comparison to controls (p< 0.001 for all). TheTable 2 Levels of thyroid hormones, TSH and anti-thyroid antibo
Parameters SLE
FT3 (pg/ml) 3.2 ± 1.2
FT4 (ng/dl) 1.9 ± 0.6
TSH (lIU/ml) 3.5 ± 1.4
Anti-TPO (IU/ml) 75 ± 13.8
Anti-TG (IU/ml) 2.2 ± 0.4
p< 0.000, very highly signiﬁcant.mean serum anti-TPO and anti-TG antibodies levels were
higher than the normal range and were statistically elevated
(p< 0.001 for both) among patients in comparison to
controls, as shown in Table 2.
3.3. Prevalence of thyroid dysfunction among patients
and controls
According to thyroid hormones and TSH levels, we had 82
(82%) patients with euthyroid state versus 96 (96%) among
the control group (p= 0.002). Accordingly, we had 18 (18%)
patients with thyroid dysfunction versus 4 (4%) among the con-
trol group (p= 0.003). Patients with thyroid dysfunction were
classiﬁed into 10 (10%) patients with SCHT versus none of con-
trols (p= 0.002), 4 (4%) patients with clinical hypothyroidism
(CHT) versus none of controls (p= 0.121), and 4 patients with
subclinical hyperthyroidism versus 4 among controls. All pa-
tients with thyroid dysfunction were females.
3.4. Prevalence of ATA among patients and controls
Anti-TPO antibody was detected in 35 (35%) patients versus
11 (11%) among the controls (p< 0.001). Anti-TG antibody
was detected in 22 (22%) patients versus 6 (6%) among the
controls (p= 0.001). Both antibodies were found together in
20 (20%) patients. Anti-TPO antibody was found in all pa-
tients with SCHT and all patients with CHT in contrast to
none of the controls (p = 0.002, p= 0.121 respectively).
Anti-TG antibody was found in 5 (50%) patients with SCHT
and in all patients with CHT in contrast to none of the con-
trols (p= 0.059, p= 0.121 respectively). Among patients with
euthyroid state (82 patients), 21 (25.6%) had anti-TPO anti-
body and 13 (15.85%) had anti-TG antibody versus 11%
and 6% among controls respectively (p> 0.05 for both). Pa-
tients and controls with subclinical hyperthyroidism had no
anti-thyroid antibody.
It was found that patients with anti-TPO and anti-TG anti-
bodies had statistically elevated TSH levels (p< 0.001) in
comparison to those without antibodies. FT3 and FT4 levels
showed no signiﬁcant differences among patients with and
without either of antibodies. This is shown in Table 3.3.5. The relation between thyroid status and age, disease
duration and BMI
SCHT and CHT were found to be signiﬁcantly associated with
aging (p= 0.01, p= 0.02 respectively) and longer disease
duration (p< 0.001 for both) and associated with high BMI
(p< 0.001 for both) in comparison to euthyroid patients.dies in SLE patients and controls.
Control (No. 100) p Value (No. 100)
1.83 ± 0.56 0.000
1.28 ± 0.28 0.000
1.92 ± 0.82 0.000
45 ± 2.7 0.000
0.8 ± 0.3 0.000
Table 3 Thyroid hormone and TSH levels among patients with and without antithyroid antibodies.
Parameter SLE with anti-TPO antibodies (N= 35) SLE without anti-TPO antibodies (N= 65) p Value
FT3 (pg/ml) 1.1 ± 0.35 1.22 ± 0.21 NS
FT 4 (ng/ml) 1.1 ± 0.24 1.21 ± 0.52 NS
TSH (lIU/ml) 3.43 ± 1.7 1.62 ± 0.75 0.000
SLE with anti-TG antibodies (N= 22) SLE without anti-TG antibodies (N= 78) p Value
FT3 (pg/ml) 1.52 ± 0.32 1.31 ± 0.54 NS
FT 4 (ng/ml) 1.31 ± 0.54 1.41 ± 0.25 NS
TSH (lIU/ml) 4.35 ± 1.9 1.81 ± 0.8 0.000
p< 0.000, very highly signiﬁcant.
Table 4 Comparison between SLE patients according to the thyroid state regarding age, BMI and disease duration.
Parameters Euthyroid N= 82 SCHT N= 10 CHT N= 4 Subclinical hyperthyroid N= 4 p Value
Mean ± SD Mean ± SD Mean ± SD Mean ± SD p1 p2 p3
Age (years) 28.1 ± 13 39.4 ± 16.2 44.2 ± 20.8 35.5 ± 12.4 0.01 0.02 NS
BMI (kg/m2) 26.4 ± 1.4 28.4 ± 2.3 31.4 ± 3.3 21.4 ± 1.3 0.000 0.000 0.000
Disease duration (years) 7.5 ± 2.6 12.0 ± 6.3 17.5 ± 1.5 8.5 ± 0.6 0.000 0.000 NS
BMI, body mass index; SCHT, subclinical hypothyroidism; CHT, clinical hypothyroidism; p1: SCHT vs. euthyroid; p2: CHT vs. euthyroid; p3:
subclinical hyperthyroid vs. euthyroid; p< 0.05, signiﬁcant; p< 0.000, very highly signiﬁcant.
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cant reduction in BMI in comparison to euthyroid patients, as
shown in Table 4.3.6. Musculoskeletal manifestations of SLE and thyroid
dysfunctions
Different musculoskeletal manifestations were compared in lu-
pus patients with different thyroid dysfunctions against those
with euthyroid state as shown in Table 5. Ritchie-articular in-
dex with scoreP5 was found in 9 patients with SCHT versus 7
with euthyroid state (90% vs. 8.5%, p< 0.001), polyarthritis
and ﬁbromyalgia were found in 10 for each versus none
(100% vs. 0%, p< 0.001) and positive Phalen’s test was found
in 8 versus none (80% vs. 0%, p< 0.001).
Comparing patients with CHT against those with euthyroid
state revealed that Ritchie-articular index with score P5 was
found in 4 patients with CHT versus 7 with euthyroid stateTable 5 Musculoskeletal signs in SLE patients according to the th
Parameter Euthyroid N= 82 SCHT N= 10 CHT N= 4
RAI/53 0 53 0
1–4 22 1
5–10 7 8
11–22 0 1
Swollen joints/44 0 82 0
1–4 0 0
P5 0 10
Fibromyalgia Positive 0 10
Phalen’s test Positive 0 8
RAI, Ritchie-articular index; p= 0.01, highly signiﬁcant; p< 0.000, ver(100% vs. 8.5%, p< 0.001), oligoarthritis/polyarthritis was
found in 3 versus none (75% vs. 0%, p< 0.001), ﬁbromyalgia
and positive Phalen’s test were found in 4 for each versus none
(100% vs. 0%, p< 0.001).
On comparing patients with subclinical hyperthyroidism
against those with euthyroid state, it was found that a
signiﬁcant Ritchie-articular index with score P5 in 3 among
the former group versus 7 among the latter group (75% vs.
8.5%, p< 0.001) and monoarthritis/oligoarthritis in 4 versus
none in the latter group (100%, p< 0.001). None of patients
with subclinical hyperthyroidism had ﬁbromyalgia or positive
Phalen’s test.
4. Discussion
While thyroid diseases and thyroid antibodies are not included
in the lupus classiﬁcation criteria, it is realistic to investigate
whether patients with SLE have higher prevalence of thyroid
disease than that in the general population [19]. However,yroid state.
Subclinical hyperthyroid N= 4 p Value
p1 p2 p3
0 0 – – –
0 1 0.6 – 0.6
2 2 0.000 0.000 0.000
2 1 0.000 0.000 0.01
1 0 – – –
2 4 – 0.000 0.000
1 0 0.000 0.000 –
4 0 0.000 0.000 –
4 0 0.000 0.000 –
y highly signiﬁcant.
Thyroid dysfunction and anti-thyroid antibodies in Egyptian patients with systemic 177divergence still exists in relation to the prevalence and still a
matter of controversy.
The prevalence of thyroid dysfunction was signiﬁcantly
more among lupus patients than controls (18% vs. 4%,
p= 0,003). Hypothyroidism was more common than hyper-
thyroidism (14% vs. 4%). SCHT (10%) was the most common
thyroid dysfunction in our lupus patients followed by CHT
(4%). Although SCHT and CHT were not detected in the con-
trols, the former only showed a signiﬁcant prevalence in com-
parison to controls (p= 0.002) and the latter did not show
(p> 0.05). This might be related to their small number. Sub-
clinical hyperthyroidism was present in 4% of lupus patients
as well as the controls. Previous studies showed discrepancies
in relation to the thyroid dysfunction types which are more
commonly met [2]. While our results regarding the prevalence
of SCHT and CHT came in agreement with previous studies
[2,20–23], they showed a higher prevalence when compared
to lupus cohort of another studies [24–28] or lower prevalence
when compared to others [29,30].
ATA levels were signiﬁcantly elevated in lupus patients in
comparison to controls (p< 0.001). ATA were found in
37% of lupus patients, in accordance with Boey [26]. On the
other hand, our ATA results were much lower [29,31,32] or
higher in contrast to others [33,34]. Anti-TPO was present in
35% of lupus patients and this prevalence was found to be
higher [23,35] or lower than others [36]. In addition, anti-TG
was found in 22% of our lupus patients which came in accor-
dance with the study of Chan et al. [20]. On the other hand,
our anti-TG prevalence was higher [23,36] or lower than others
[35,37]. Eleven percent of our controls were positive for anti-
TPO which came in accordance with earlier studies [23,38] or
higher than others [39,40].
All patients (18%) with thyroid dysfunction were females
and had autoimmune thyroid disease being positive to one
or both ATA. Anti-TPO was detected in all patients with
SCHT and CHT while anti-TG was found in half of SCHT
and all CHT patients. Patients with subclinical hyperthyroid-
ism were negative for both ATA. Among euthyroid patients,
anti-TPO was found in 25.6% and anti-TG was found in
15.85%.
According to the Nordyke and coworkers [41], and Diaz
and Lglesias [42], SCHT can change into CHT. This change
was found to be associated with aging, female gender and with
positive ATA [20,43,44]. Accordingly, follow up of our SCHT
patients may with time (i.e. aging) show this change into CHT,
especially that all our lupus patients with SCHT are females
and have positive ATA. It is also possible that our euthyroid
patients, especially the females who have positive ATA, may
through the next coming years (i.e. aging) develop SCHT or
CHT. Our study showed that the hypothyroidism, either
SCHT or CHT, was associated with aging and longer disease
duration and all of them were females and had ATA in accor-
dance to previous mentioned studies [20,43,44].
Patients with ATA had a signiﬁcant increased TSH level
than those without ATA (p< 0.001). This appeared to be
logic because most patients with ATA had hypothyroidism
(14/20, 70%) and this is usually associated with increased level
of TSH as a part of the hypothyroid diagnosis [45].
In the present study, we tried to discover how different lu-
pus musculoskeletal manifestations were affected by thyroid
dysfunction. Ritchie-articular index score was found to be sig-
niﬁcantly elevated in patients with SCHT, CHT (p< 0.001)and subclinical hyperthyroid (p< 0.01) in comparison to pa-
tients with euthyroid state. Moreover, swollen joint count
was found to be signiﬁcantly elevated in patients with SCHT
and CHT (p< 0.001) compared to the euthyroid patients. Pol-
yarthritis in particular, was signiﬁcantly associated with SCHT
(p< 0.001), while monoarthritis/oligoarthritis was signiﬁ-
cantly associated with CHT (p< 0.001). Fibromyalgia was a
common companion of lupus and has a considerable impact
on morbidity [46]. It was detected in 14% of our patients, all
of them had hypothyroidism and of highly signiﬁcant result
in comparison to the euthyroid patients. This was a little bit
lower than previous studies [47,48]. Finally, positive Phalen’s
test for diagnosing carpal tunnel syndrome was found in
12% of patients and all had hypothyroidism with very high
statistical signiﬁcant difference (p< 0.001) compared to the
euthyroid patients.
It can be concluded that hypothyroidism is more often seen
in lupus patients than normal population and signiﬁcantly
associated with the musculoskeletal manifestations of the dis-
ease especially the Ritchie-articular index, arthritis, ﬁbromyal-
gia and Phalen’s test. Thyroid function tests and ATA should
be done in all lupus patients, as their assessment may add ben-
eﬁt to reduce the risk of musculoskeletal related morbidity.Conﬂict of interest
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